Clinical Trial Update: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of fostamatinib in persistent/chronic immune thrombocytopenic purpura (ITP) completed, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• Tavlesse (fostamatinib disodium)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Immune Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2019-01-25